Exelixis Aktie
WKN: 936718 / ISIN: US30161Q1040
23.06.2025 20:22:29
|
Exelixis Stock Jumps Nearly 9% On Positive Phase 3 Colorectal Cancer Trial Results
(RTTNews) - Exelixis, Inc. (EXEL) is trading at $43.77, up 8.41 percent, or $3.40 on Monday, after the company announced positive topline results from its Phase 3 STELLAR-303 trial in metastatic colorectal cancer.
The stock opened at $49.36 and has traded between $43.03 and $49.40 so far today. Volume has surged to 6.82 million shares, well above the average of 2.97 million. Exelixis shares have ranged between $21.82 and $49.40 over the past 52 weeks.
The study showed that its investigational drug Zanzalintinib, combined with Genentech's Tecentriq, significantly improved overall survival compared to Bayer's Regorafenib in previously treated patients.
)

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Exelixis Inc.mehr Nachrichten
Analysen zu Exelixis Inc.mehr Analysen
Aktien in diesem Artikel
Exelixis Inc. | 37,70 | -0,34% |
|